News
Women’s health start-up launches perimenopause hormone kit
Oova aims to give women and their physicians more insights into their perimenopause journey
The US women’s health start-up Oova has launched an at-home hormone kit to support women during perimenopause.
The kit, which tests multi-hormone biomarkers including oestrogen (E3G), comes with an app that tracks women’s data in real time.
Unlike other options on the market, which rely on blood or FSH-only urine tests that only capture a moment in time, Oova says its users are able to measure their hormone fluctuations across a 15-day period throughout a single cycle and their progress month-over-month. This, the company argues, could give women and their physicians insights into their perimenopause journey.
“There are significant gaps in hormone health research, especially as it relates to perimenopause,” says Amy Divaraniya, founder and CEO of Oova.
“We know doctors and patients alike are missing methods to pinpoint where someone is in their journey and identify how symptoms correspond to hormone changes, which often leaves women navigating this life phase in the dark. With the perimenopause hormone kit, women can better understand their bodies, while tracking data that empowers them to make informed decisions with their physicians.”
The Oova test strips are scanned into an app which utilises AI and machine learning to interpret the scan into results. Over time, the company claims its predictive algorithms begin to learn the nuances of every woman’s hormone profile to help her better manage her health.
Insights include measuring perimenopausal hormone activity, tracking physical symptoms, indicating fertility and confirming ovulation for those trying to conceive during perimenopause. It also helps users monitor their hormone patterns when starting hormone replacement therapy (HRT).
“Oova’s test serves as a significant leap forward in healthcare,” says Dr Beck Hoehn, founder of the California-based alternative healthcare practice Mighty River Wellness and advisor to Oova.
“In this stage of women’s health that has traditionally been passed over, Oova’s perimenopause kit equips both the patient and clinician with real-time, accurate insight needed to navigate the complexities with confidence and clarity.”
The launch comes weeks after Oova announced a US$10.3m funding round, led by funding from Spero Ventures, for a new subscription model.
To receive the Femtech World newsletter, sign up here.
Type 2 diabetes diagnoses are rising twice as fast in women under 40 as in women over 40, new data shows.
Type 2 diabetes is a serious condition and can lead to complications such as heart attacks and strokes. When it develops in younger people, it can be more aggressive and have more severe and acute effects.
Diagnoses in women under 40 rose by 47 per cent between 2017/18 and 2023/24. By comparison, diagnoses rose by 22 per cent in women aged 40 to 79.
During the same period, type 2 diabetes diagnoses in men under 40 increased by 34 per cent.
Diabetes UK said it is concerned about the follow-up care offered to women who have had gestational diabetes, also known as GDM, which increases the risk of developing type 2 diabetes after pregnancy.
Gestational diabetes is high blood sugar that develops during pregnancy and usually goes away after birth, but it raises the risk of type 2 diabetes later.
Colette Marshall, chief executive at Diabetes UK, said: “These figures should be a wake-up call. Type 2 diabetes is rising twice as fast in younger women compared to older women, and a crucial opportunity for prevention is being missed. Every diagnosis is life-changing, but when it develops in younger people, type 2 diabetes is even more aggressive.
“Pregnancy shouldn’t be a pathway to ill health. Yet despite facing a much higher risk of type 2 diabetes, too many women with GDM receive little or no follow-up care after pregnancy.
“As the Government turns its Strategy into action, support for women who have had gestational diabetes must not be overlooked.”
Last year, the NHS published the first national GDM audit for England in 2024/25, which revealed inconsistencies in follow-up care.
Only 57 per cent of women with GDM received an annual HbA1c test, which should be offered to every woman with GDM.
An HbA1c test measures average blood sugar levels over the previous two to three months.
Only 4.5 per cent of women had received support through the NHS Diabetes Prevention Programme.
The report also found that 11 per cent of women developed prediabetes within five years of having GDM, while 15 per cent developed type 2 diabetes within 10 years.
Prediabetes means blood sugar levels are higher than normal and a person has a higher risk of developing type 2 diabetes.
A recent survey funded by Diabetes UK also found that more than a third of women with GDM felt abandoned by healthcare services after giving birth.
If you live in England and have had gestational diabetes, you can self-refer to the NHS Diabetes Prevention Programme, which supports people at risk of developing type 2 diabetes. If you live in Northern Ireland, Scotland or Wales, you can speak to your GP about support.
Diabetes UK has written to women’s health minister Baroness Merron calling for urgent improvements to postnatal support for those diagnosed with GDM during pregnancy.
GDM affects between 10 and 20 per cent of pregnant women, but Diabetes UK said cases have long been underreported and UK-wide data on the condition has not been readily available.
The charity said poor follow-up care for women who have had GDM may be contributing to rising rates of type 2 diabetes in younger women.
It is calling for consistent postnatal follow-ups for women after GDM, more referrals to the NHS Diabetes Prevention Programme, greater accountability for improvements in postnatal care, and action on inequalities affecting women from deprived and minority ethnic communities.
Smartwatch data may help track menopause sleep changes after researchers analysed more than 94,000 nights of Apple Watch sleep records.
The study analysed more than 94,000 nights of sleep data from 338 participants in the Apple Women’s Health Study.
It found that many participants spent more time awake during the night in the 12 months before and after their final logged menstrual period.
For the past several years, Apple has used the Apple Watch to support large-scale health studies through the Apple Research app.
These include the Apple Women’s Health Study, the Apple Heart and Movement Study, and the Apple Hearing Study, which launched in 2019 with research partners including Harvard, Brigham and Women’s Hospital, the American Heart Association and the University of Michigan.
In February 2025, Apple said those studies had grown to more than 350,000 participants across the US.
Recently, researchers at Harvard T.H. Chan School of Public Health published results on how sleep patterns change during perimenopause.
The study looked at wake after sleep onset, or WASO, which measures how much time a person spends awake after first falling asleep.
In the 18 months leading up to menopause, 60 per cent of women with sleep tracking data showed increased WASO compared with the previous six months.
The average increase was 7 per cent.
Researchers also found that, in the 12 months before and after the last logged menstrual period, participants spent about 0.8 per cent more of their sleep time awake after menopause than before.
However, the findings varied widely between participants.
Some women had much larger increases in time awake after menopause, while others had no meaningful sleep change at all.
The researchers said this reflects the fact that each person experiences perimenopause and menopause differently.
Participants who tracked sleep also logged menopause symptoms.
Hot flushes were reported by 82.3 per cent of participants, irritability by 68.1 per cent, mental exhaustion by 65.7 per cent and sexual symptoms by 65.6 per cent.
Among participants with more severe menopause symptoms, the symptoms most closely linked with worse sleep were bladder symptoms, joint symptoms, heart discomfort and depressive symptoms.
The researchers also shared recommendations that may help women sleep better during perimenopause.
These include maintaining a cool sleeping environment, keeping a consistent sleep schedule, getting regular movement, avoiding common bladder irritants and limiting fluids in the hours before bedtime, and prioritising relaxation or mindfulness techniques as part of a bedtime routine.
A genomic test may help some women with breast cancer avoid chemotherapy, with near-identical outcomes in an international trial.
The findings suggest patients with a low test score could be treated with hormone therapy alone without increasing the risk of their cancer returning.
Researchers said the results could support more personalised treatment decisions and spare some women the side-effects of chemotherapy.
Prof Rob Stein, the trial’s chief investigator and a professor of breast oncology at UCL, said: “Optima addresses a longstanding challenge in breast cancer care: identifying who truly benefits from chemotherapy and who does not.
“Our findings show that many patients can safely avoid chemotherapy without compromising their outcomes.
“These results mark an important and significant step toward more personalised treatment.
“The trial has successfully used tumour biology to guide decisions rather than relying solely on traditional clinical features.”
Breast cancer treatment usually involves surgery to remove tumours. Chemotherapy is then often recommended if doctors believe there is a risk the disease will return.
Chemotherapy can cause side-effects including hair loss, rashes, nausea, insomnia and fatigue. Some women may also face longer-term consequences such as infertility, cognitive impairment or early menopause.
The Optima trial followed more than 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand.
The trial was led by University College London.
One woman who took part in the trial told the Guardian that being able to skip chemotherapy felt “like Christmas”. Nine years after being diagnosed, taking the test and skipping chemotherapy, she is healthy and enjoying a full and active life.
The trial tested whether a genomic test could identify which patients need chemotherapy and which could safely avoid it.
The Prosigna test, made by diagnostics company Veracyte, analyses the activity of 50 genes in tumour tissue. It identifies the molecular subtype of the cancer and gives a score estimating the risk of breast cancer returning in the next 10 years.
The randomised trial involved 4,429 patients aged 40 or over with hormone-positive breast cancer. Hormone-positive breast cancer grows in response to hormones such as oestrogen or progesterone. It is the most common form of breast cancer, accounting for up to 80 per cent of cases globally.
Participants were assigned to one of two groups. In the standard treatment group, patients received chemotherapy followed by hormone therapy.
In the second group, patients had their tumours analysed using the genomic test. Those with a high score received chemotherapy and hormone therapy. Those with a low score received hormone therapy alone.
Radiotherapy and other treatments were given as usual in both groups.
In the second group, outcomes were very similar whether chemotherapy was given or not. Five years after treatment, 95 per cent of patients who had chemotherapy and hormone therapy were alive and free from breast cancer recurrence, while 94 per cent of those who skipped chemotherapy were also alive and recurrence-free.
The findings suggest chemotherapy offered little or no additional benefit for patients with low test scores.
Some men also took part in the study, but researchers said there were too few to draw firm conclusions for this group.
The trial received funding from the National Institute for Health and Care Research, Veracyte and cancer charities.
Prof Iain MacPherson, a co-chief investigator and professor of breast oncology at the University of Glasgow, said: “Optima provides robust, practice-changing evidence that we can safely reduce the use of chemotherapy for many patients with hormone-sensitive breast cancer.
“These findings represent a major step forward in delivering more personalised, precise care, ensuring that treatment decisions are driven by what will genuinely improve outcomes for patients, while avoiding unnecessary toxicity.
“The potential impact for both patients and health services is substantial.”
Menopause7 days agoPerimenopause misinformation ‘putting women at risk’
Opinion4 weeks agoWhat Maternal Mental Health Month reveals about where postpartum support actually breaks down
News4 weeks agoNIH Grant terminations disproportionately impact minority scientists, research finds
Wellness4 weeks agoWUKA brings Period-Positive Pool Party to London Aquatics Centre to keep girls swimming through puberty
Insight3 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events4 weeks agoWHIS 2026 unveils agenda and first speakers for the leading women’s health summit
Menopause4 weeks agoCBT shows promise for menopause insomnia and hot flashes
Insight4 weeks agoOnline abuse and deepfakes ‘pushing women out of public life’